ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SCTB39G

A development code. Also written as “SCTB41+SCTB39G”.

Its studies are led by Sinocelltech Group.

Furthest: phase 2, since Jul 11, 20252 company-led studies, 2 open or runningNext primary completion: Sep 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinocelltech Group22 open or runningphase 2since Jul 11, 2025Jul 11, 2025Sep 26, 2027phase 2 · NCT07077252

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2025First study: phase 2 study in Advanced Malignant Solid TumorFirst studyNCT07077252 · 30 planned · China
  2. Jun 18, 2026Phase 2 study in Advanced Malignant Solid TumorsNCT07665970 · 112 planned

Ahead

  1. Sep 26, 2027Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07077252
  2. Jun 30, 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorsNCT07665970

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07665970Advanced Malignant Solid Tumors2Not yet recruitingJun 30, 2029112
NCT07077252Advanced Malignant Solid Tumor · China2Not yet recruitingSep 26, 202730

How it is read

Names in the registry

  • “SCTB41+SCTB39G”, 1 entry
  • “SCTB39G”, 1 entry

Codes read as this program: SCTB39G.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.